Molecular Partners to Present Initial Phase 1/2a Data on MP0712 in Lung Cancer, Other Solid Tumors

PUBT · 1d ago
Molecular Partners to Present Initial Phase 1/2a Data on MP0712 in Lung Cancer, Other Solid Tumors
  • Molecular Partners will present initial MP0712 Phase 1/2a dose-escalation results at the North America Conference on Lung Cancer on December 5, 2026.
  • The first-in-human trial evaluates the candidate, co-developed with Orano Med, in small cell lung cancer and other DLL3-expressing solid tumors.
  • A November 7 presentation at the 2026 SNMMI Theranostics Conference will cover lessons from advancing MP0712 into clinical testing.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Molecular Partners AG published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611050100PRIMZONEFULLFEED9870665) on November 05, 2026, and is solely responsible for the information contained therein.